The European health regulator has started reviewing data on AstraZeneca and Oxford University's potential Covid-19 vaccine in real time, the first of such moves aimed at speeding up any approval process in the region for a vaccine.
The European Medicines Agency (EMA) said today its human medicines committee is evaluating the first batch of non-clinical data on the vaccine from laboratory studies, and will continue to do so until sufficient data is available for a final decision.
The EMA uses "rolling reviews" to speed up evaluations of promising drugs or vaccines during a public health emergency, subverting the typical process by assessing data as it is submitted, rather than waiting for all data to be made available along with a formal